Heart disease is more common in people over 65, but treatments are better than ever. That can complicate decision-making for older heart patients.

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Inhibiting GLS1 reduced high blood pressure in the right side of the heart of PAH rats and improved various measures of heart ...

High blood pressure is a major risk factor for heart disease. Here are some common questions you may have about blood ...

Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the ...

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Published in the Journal of the American Heart Association, the study showcases the potential of AI-powered heart sound ...

Eko Health has been advancing the use of artificial intelligence to help providers detect the early signs of disease, ...

In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

If you're concerned about your blood pressure, be sure to talk to your doctor. The force of blood that pushes against artery walls every time the heart beats. Blood pressure is often measured ...